Janux Executive Sells 16,665 Shares for $501,000 Through Options Exercise
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 04 2025
0mins
Should l Buy JANX?
Source: Fool
Insider Transaction Details: Meyer Andrew Hollman, Chief Business Officer at Janux Therapeutics, exercised 16,665 stock options and sold the shares for approximately $501,000 on October 28, 2025, representing 16.87% of his direct holdings prior to the transaction.
Nature of the Transaction: This was a routine "exercise-and-sell" maneuver, allowing Hollman to convert stock options into cash while managing tax liabilities, without altering his net equity stake in the company.
Post-Transaction Holdings: After the sale, Hollman retains 82,139 shares valued at around $2.44 million, indicating a significant ongoing investment in Janux Therapeutics.
Market Context and Risks: Janux Therapeutics, a clinical-stage biotech firm, faces inherent stock volatility, exemplified by a 50% drop in share value following disappointing trial results, highlighting the risks associated with investing in such companies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JANX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JANX
Wall Street analysts forecast JANX stock price to rise
16 Analyst Rating
15 Buy
1 Hold
0 Sell
Strong Buy
Current: 13.440
Low
25.00
Averages
55.25
High
150.00
Current: 13.440
Low
25.00
Averages
55.25
High
150.00
About JANX
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Janux Therapeutics Reports Increased Q4 Losses
- Earnings Overview: Janux Therapeutics reported a fourth-quarter loss of $42.40 million, translating to a loss of $0.51 per share, which is a significant increase from last year's loss of $20.22 million or $0.36 per share, indicating heightened pressure on the company's profitability.
- Year-over-Year Comparison: The loss increased by 109% compared to the same period last year, highlighting intensified challenges in cost control and revenue growth, which may impact future financing capabilities and investor confidence.
- Market Reaction: The larger-than-expected loss may lead investors to adopt a cautious outlook on the company's future financial performance, resulting in increased stock price volatility and affecting the company's standing in the capital markets.
- Strategic Implications: Ongoing losses may prompt the company to reassess its R&D and operational strategies to seek more effective cost management and revenue growth pathways, thereby ensuring survival and growth in the highly competitive biopharmaceutical industry.
See More
Janux Therapeutics Q4 Earnings Beat Expectations
- Earnings Surprise: Janux Therapeutics reported a Q4 GAAP EPS of -$0.51, beating expectations by $0.16, indicating some financial resilience despite ongoing losses.
- Cash Reserves Decline: As of December 31, 2025, Janux's cash and cash equivalents totaled $966.6 million, down from $1.03 billion a year earlier, reflecting significant operational and R&D expenditures.
- Rating Downgrade Impact: Following the latest Phase 1 JANX007 data update, Janux's stock rating was downgraded to 'Hold', which may affect investor confidence and lead to short-term stock price volatility as the market reassesses its 'best-in-class' status.
- Partnership Progress: Bristol Myers has inked a licensing deal with Janux for cancer therapy, indicating continued market interest in Janux's technology, which could provide new revenue streams and enhance its competitive position.
See More
Janux Therapeutics and Bristol Myers Squibb Sign $800 Million Collaboration Agreement
- Collaboration Agreement: Janux Therapeutics has entered into an exclusive worldwide license agreement with Bristol Myers Squibb, receiving up to $50 million in upfront and near-term milestone payments, with potential total payments reaching approximately $800 million, significantly enhancing its capabilities in developing tumor immunotherapies.
- Clinical Development Support: The collaboration allows Janux to complete preclinical development up to Investigational New Drug (IND) submission, while Bristol Myers Squibb will take charge of subsequent development and commercialization, expected to accelerate the market introduction of new drugs.
- Positive Market Reaction: Following the announcement of the agreement, Janux's stock rose by 7.69% to $14.29, despite a 66.97% decline over the past 12 months, indicating that the collaboration is seen as a strong validation of its tumor-activated platform, potentially improving investor confidence.
- Optimistic Analyst Ratings: Although Clear Street downgraded its rating to Hold with a target price of $12.00, the overall analyst consensus remains a Buy with an average target price of $61.76, reflecting market confidence in Janux's future development.
See More
Janux Therapeutics (JANX) Partners with Bristol Myers Squibb for Tumor-Activated Therapy Development
- Strategic Collaboration: Janux Therapeutics has entered a partnership with Bristol Myers Squibb to focus on a yet-to-be-disclosed solid tumor target across multiple cancer types, aiming to expand treatment options for patients globally and enhance the company's market position in oncology.
- Development Management Division: Under the agreement, Janux will handle preclinical development through IND submission, while Bristol Myers Squibb will hold the IND and oversee subsequent clinical development and global commercialization, ensuring efficient resource utilization and specialized management.
- Positive Market Reaction: Following the announcement, Janux Therapeutics' stock traded over 8% higher in Thursday's premarket, reflecting market optimism regarding the collaboration's prospects, which may enhance the company's future fundraising capabilities and investor confidence.
- Global Commercialization Potential: This partnership not only strengthens Janux's R&D capabilities in oncology but also provides Bristol Myers Squibb with a new product line, expected to drive both companies' competitiveness and market share in the global market.
See More
Janux Therapeutics (JANX) Partners with Bristol Myers Squibb for $50M Collaboration on Solid Tumor Therapy
- Collaboration Agreement: Janux Therapeutics has signed an exclusive worldwide license agreement with Bristol Myers Squibb to advance a novel therapy for solid tumors, which is expected to significantly enhance both companies' market competitiveness in oncology.
- Financial Support: Under the agreement, Janux will receive up to $50 million in upfront and near-term milestone payments, along with approximately $800 million in development, regulatory, and commercial milestones, thereby strengthening the company's financial flexibility.
- Technology Integration: Janux's proprietary tumor-activated platforms (TRACTr, TRACIr, and ARM) will be combined with Bristol Myers Squibb's clinical development expertise, which is anticipated to accelerate the clinical progress of new therapies and improve treatment outcomes, further solidifying its position in the tumor immunotherapy space.
- Clinical Trial Involvement: Janux will remain actively involved in the first Phase 1 clinical study, ensuring the efficacy and safety of its technology, which not only helps enhance the company's reputation but may also pave the way for future product development.
See More
Janux Therapeutics Secures Exclusive License Agreement with Bristol Myers Squibb, Potential Earnings Up to $800 Million
- Collaboration Agreement: Janux Therapeutics has entered into an exclusive worldwide license agreement with Bristol Myers Squibb, focusing on developing a tumor antigen therapeutic for various cancer types, which is expected to significantly enhance both companies' market competitiveness in oncology.
- Financial Support: Under the agreement, Janux is eligible for up to $50 million in upfront and near-term milestone payments, along with approximately $800 million in development, regulatory, and commercial milestones, ensuring robust funding for future research and development.
- R&D Responsibility: Janux will handle preclinical development up to the submission of an Investigational New Drug (IND) application, with the successful completion of this phase laying the groundwork for Bristol Myers Squibb's clinical development and commercialization, highlighting the close collaboration between the two firms.
- Market Potential: This partnership not only provides Janux with substantial financial backing but also enhances its influence in the cancer treatment market through collaboration with Bristol Myers Squibb, potentially accelerating the market entry of new therapies.
See More
Janux Therapeutics Reports Increased Q4 Losses
- Earnings Overview: Janux Therapeutics reported a fourth-quarter loss of $42.40 million, translating to a loss of $0.51 per share, which is a significant increase from last year's loss of $20.22 million or $0.36 per share, indicating heightened pressure on the company's profitability.
- Year-over-Year Comparison: The loss increased by 109% compared to the same period last year, highlighting intensified challenges in cost control and revenue growth, which may impact future financing capabilities and investor confidence.
- Market Reaction: The larger-than-expected loss may lead investors to adopt a cautious outlook on the company's future financial performance, resulting in increased stock price volatility and affecting the company's standing in the capital markets.
- Strategic Implications: Ongoing losses may prompt the company to reassess its R&D and operational strategies to seek more effective cost management and revenue growth pathways, thereby ensuring survival and growth in the highly competitive biopharmaceutical industry.
See More
Janux Therapeutics Q4 Earnings Beat Expectations
- Earnings Surprise: Janux Therapeutics reported a Q4 GAAP EPS of -$0.51, beating expectations by $0.16, indicating some financial resilience despite ongoing losses.
- Cash Reserves Decline: As of December 31, 2025, Janux's cash and cash equivalents totaled $966.6 million, down from $1.03 billion a year earlier, reflecting significant operational and R&D expenditures.
- Rating Downgrade Impact: Following the latest Phase 1 JANX007 data update, Janux's stock rating was downgraded to 'Hold', which may affect investor confidence and lead to short-term stock price volatility as the market reassesses its 'best-in-class' status.
- Partnership Progress: Bristol Myers has inked a licensing deal with Janux for cancer therapy, indicating continued market interest in Janux's technology, which could provide new revenue streams and enhance its competitive position.
See More
Janux Therapeutics and Bristol Myers Squibb Sign $800 Million Collaboration Agreement
- Collaboration Agreement: Janux Therapeutics has entered into an exclusive worldwide license agreement with Bristol Myers Squibb, receiving up to $50 million in upfront and near-term milestone payments, with potential total payments reaching approximately $800 million, significantly enhancing its capabilities in developing tumor immunotherapies.
- Clinical Development Support: The collaboration allows Janux to complete preclinical development up to Investigational New Drug (IND) submission, while Bristol Myers Squibb will take charge of subsequent development and commercialization, expected to accelerate the market introduction of new drugs.
- Positive Market Reaction: Following the announcement of the agreement, Janux's stock rose by 7.69% to $14.29, despite a 66.97% decline over the past 12 months, indicating that the collaboration is seen as a strong validation of its tumor-activated platform, potentially improving investor confidence.
- Optimistic Analyst Ratings: Although Clear Street downgraded its rating to Hold with a target price of $12.00, the overall analyst consensus remains a Buy with an average target price of $61.76, reflecting market confidence in Janux's future development.
See More
Janux Therapeutics (JANX) Partners with Bristol Myers Squibb for Tumor-Activated Therapy Development
- Strategic Collaboration: Janux Therapeutics has entered a partnership with Bristol Myers Squibb to focus on a yet-to-be-disclosed solid tumor target across multiple cancer types, aiming to expand treatment options for patients globally and enhance the company's market position in oncology.
- Development Management Division: Under the agreement, Janux will handle preclinical development through IND submission, while Bristol Myers Squibb will hold the IND and oversee subsequent clinical development and global commercialization, ensuring efficient resource utilization and specialized management.
- Positive Market Reaction: Following the announcement, Janux Therapeutics' stock traded over 8% higher in Thursday's premarket, reflecting market optimism regarding the collaboration's prospects, which may enhance the company's future fundraising capabilities and investor confidence.
- Global Commercialization Potential: This partnership not only strengthens Janux's R&D capabilities in oncology but also provides Bristol Myers Squibb with a new product line, expected to drive both companies' competitiveness and market share in the global market.
See More
Janux Therapeutics (JANX) Partners with Bristol Myers Squibb for $50M Collaboration on Solid Tumor Therapy
- Collaboration Agreement: Janux Therapeutics has signed an exclusive worldwide license agreement with Bristol Myers Squibb to advance a novel therapy for solid tumors, which is expected to significantly enhance both companies' market competitiveness in oncology.
- Financial Support: Under the agreement, Janux will receive up to $50 million in upfront and near-term milestone payments, along with approximately $800 million in development, regulatory, and commercial milestones, thereby strengthening the company's financial flexibility.
- Technology Integration: Janux's proprietary tumor-activated platforms (TRACTr, TRACIr, and ARM) will be combined with Bristol Myers Squibb's clinical development expertise, which is anticipated to accelerate the clinical progress of new therapies and improve treatment outcomes, further solidifying its position in the tumor immunotherapy space.
- Clinical Trial Involvement: Janux will remain actively involved in the first Phase 1 clinical study, ensuring the efficacy and safety of its technology, which not only helps enhance the company's reputation but may also pave the way for future product development.
See More
Janux Therapeutics Secures Exclusive License Agreement with Bristol Myers Squibb, Potential Earnings Up to $800 Million
- Collaboration Agreement: Janux Therapeutics has entered into an exclusive worldwide license agreement with Bristol Myers Squibb, focusing on developing a tumor antigen therapeutic for various cancer types, which is expected to significantly enhance both companies' market competitiveness in oncology.
- Financial Support: Under the agreement, Janux is eligible for up to $50 million in upfront and near-term milestone payments, along with approximately $800 million in development, regulatory, and commercial milestones, ensuring robust funding for future research and development.
- R&D Responsibility: Janux will handle preclinical development up to the submission of an Investigational New Drug (IND) application, with the successful completion of this phase laying the groundwork for Bristol Myers Squibb's clinical development and commercialization, highlighting the close collaboration between the two firms.
- Market Potential: This partnership not only provides Janux with substantial financial backing but also enhances its influence in the cancer treatment market through collaboration with Bristol Myers Squibb, potentially accelerating the market entry of new therapies.
See More
